SHR 4849
Alternative Names: SHR-4849Latest Information Update: 09 Aug 2024
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Jun 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (unspecified route, Injection) (NCT06443489)
- 05 Jun 2024 Suzhou Suncadia Biopharmaceuticals plans a phase I trial for Solid tumour (Late-stage disease) in June 2024 (NCT06443489)
- 05 Jun 2024 Preclinical trials in Solid tumours in China (unspecified route) prior to June 2024